(primary solid tumor cohort)
This pipeline maps genes, with mutation or copy number alteration AND this alteration is highly correlated with mRNA expression, to pathways curated in the KEGG and BIOCARTA databases. It identifies pathways significantly enriched with these genes. The pipeline also identifies pathways significantly enriched with marker genes of each expression subtype of cancer.
genes with mutation: identified by the Mutation_Significance pipeline
genes with copy number alteration: identified by the CopyNumber_Gistic2 pipeline
correlation between copy number and mRNA expression: identified by the Correlate_CopyNumber_vs_mRNA pipeline
marker genes and expression subtypes: identified by the mRNAConsensusClustering pipeline
There are 20 genes with significant mutation (Q value <= 0.1) and 508 genes with significant copy number alteration (Q value <= 0.25). The identified marker genes (Q value <= 0.01 or within top 2000) are 1088 for subtype 1, 1088 for subtype 2, 1088 for subtype 3. Pathways significantly enriched with these genes (Q value <= 0.01) are identified :
5 pathways significantly enriched with genes with copy number alteration or mutation.
0 pathways significantly enriched with marker genes of gene expression subtype 1
1 pathways significantly enriched with marker genes of gene expression subtype 2
15 pathways significantly enriched with marker genes of gene expression subtype 3
Pathway | Nof Genes | Nof CNV_Mut | Enrichment | P value | Q value |
---|---|---|---|---|---|
KEGG_PARKINSONS_DISEASE | 130 | 13 | 2.2 | 0 | 0.0013 |
BIOCARTA_CHREBP2_PATHWAY | 44 | 7 | 2.7 | 0.0001 | 0.0068 |
KEGG_RNA_DEGRADATION | 55 | 8 | 2.5 | 0.0001 | 0.0068 |
KEGG_NEUROTROPHIN_SIGNALING_PATHWAY | 126 | 12 | 1.9 | 0.0001 | 0.0068 |
KEGG_SPLICEOSOME | 126 | 11 | 2 | 0.0001 | 0.0088 |
COX5A,VDAC2,VDAC3,ATP5E,UBE2G1,CASP9,NDUFS2,ATP5H,UBB,NDUFB8,ATP5F1,PARK7,SDHD
PPP2R5D,PPP2CB,PPP2R2D,YWHAB,YWHAE,PPP2R5E,PPP2R2A
LSM7,CNOT2,CNOT7,LSM1,EXOSC1,XRN2,WDR61,DCP1B
PIK3CA,RIPK2,MAPK7,KRAS,RAP1A,IKBKB,CDC42,CAMK2G,YWHAB,YWHAE,NRAS,CALM1
LSM7,CTNNBL1,HNRNPC,SNRPB2,SNW1,CRNKL1,MAGOHB,CDC5L,WBP11,PRPF8,BCAS2
Pathway | Nof Genes | Nof Marker | Enrichment | P value | Q value |
---|---|---|---|---|---|
KEGG_ECM_RECEPTOR_INTERACTION | 84 | 14 | 1.8 | 0 | 0.014 |
KEGG_FOCAL_ADHESION | 201 | 21 | 1.1 | 0.0006 | 0.095 |
KEGG_CELL_ADHESION_MOLECULES_CAMS | 134 | 15 | 1.2 | 0.0014 | 0.15 |
KEGG_TIGHT_JUNCTION | 134 | 14 | 1.1 | 0.004 | 0.24 |
KEGG_PATHWAYS_IN_CANCER | 328 | 27 | 0.77 | 0.0039 | 0.24 |
SV2B,SV2A,COL11A1,COL1A2,LAMC1,ITGA11,ITGB3,COMP,ITGB7,ITGB6,THBS2,THBS4,COL4A4,HSPG2
CTNNB1,PPP1CA,LAMC1,ITGA11,RAC1,KDR,COL11A1,THBS2,THBS4,PDGFC,COL1A2,ITGB3,DOCK1,ITGB7,ITGB6,MYLK,AKT3,SHC4,VASP,COMP,COL4A4
NCAM1,PHOX2A,CD226,ITGB7,HLA-DOA,CLDN6,NRXN1,SIGLEC1,CD80,CNTN1,CLDN2,CLDN19,CDH5,NLGN2,NLGN3
AMOTL1,CTNNB1,MPDZ,MYH4,MYH7B,PPP2R2B,PARD6B,MYH13,MYH10,CLDN6,AKT3,EPB41L1,CLDN2,CLDN19
SHH,CTNNB1,CUL2,RARB,LAMC1,RAC1,FGF5,MITF,SPI1,GLI2,GLI3,GLI1,NOS2,AKR1B1,FZD8,FOXO1,FGF12,WNT4,RALA,FGFR1,AKT3,RUNX1T1,CDK2,NCOA4,TCF7L1,COL4A4,KLK3
Pathway | Nof Genes | Nof Marker | Enrichment | P value | Q value |
---|---|---|---|---|---|
KEGG_VIRAL_MYOCARDITIS | 73 | 13 | 2 | 0 | 0.0045 |
KEGG_FOCAL_ADHESION | 201 | 23 | 1.3 | 0.0001 | 0.013 |
KEGG_ECM_RECEPTOR_INTERACTION | 84 | 13 | 1.7 | 0.0002 | 0.013 |
KEGG_LEUKOCYTE_TRANSENDOTHELIAL_MIGRATION | 118 | 16 | 1.5 | 0.0001 | 0.013 |
BIOCARTA_EIF_PATHWAY | 16 | 5 | 2.8 | 0.0005 | 0.02 |
HLA-DMB,HLA-DMA,ACTG1,CASP8,MYH4,EIF4G2,CD86,SGCD,HLA-DPA1,MYH7B,SGCA,ITGB2,MYH13
ACTG1,ROCK2,ITGA11,SPP1,LAMA1,PTEN,COL11A1,PARVG,COL6A2,THBS2,IGF1,PDGFC,MYL9,ITGAV,ITGA4,MYLK,AKT3,SHC4,PRKCB,TNC,COMP,COL4A4,BAD
SDC2,SV2B,COL11A1,TNC,ITGA11,COMP,ITGAV,COL6A2,THBS2,SPP1,COL4A4,ITGA4,LAMA1
MMP9,MMP2,ACTG1,NCF2,NCF1,ROCK2,CTNNA1,THY1,ITGB2,MYL9,ITGA4,MSN,PRKCB,VCAM1,MLLT4,CYBB
EIF6,EEF2,EIF4G2,EIF4A1,EEF2K
Pathway | Nof Genes | Nof Marker | Enrichment | P value | Q value |
---|---|---|---|---|---|
BIOCARTA_CTL_PATHWAY | 15 | 8 | 4 | 0 | 0 |
BIOCARTA_CTLA4_PATHWAY | 21 | 8 | 3.5 | 0 | 0 |
KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION | 267 | 30 | 1.6 | 0 | 0 |
KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION | 89 | 16 | 2.4 | 0 | 0 |
KEGG_NATURAL_KILLER_CELL_MEDIATED_CYTOTOXICITY | 137 | 22 | 2.1 | 0 | 0 |
PRF1,CD3D,CD247,HLA-A,FASLG,ITGB2,TRA@,B2M
CD3D,CD247,CTLA4,TRA@,PTPN11,CD86,CD80,CD28
IFNG,CCR2,CX3CR1,VEGFA,FLT3LG,CXCL9,CXCL6,ENC1,IL10RA,CD27,IL7,CCL19,CCL15,CCL13,CXCL11,IL15RA,CCL3,CCL8,TNFSF10,IL21R,FASLG,IL8RB,CXCR6,TNFRSF9,ACVR2B,TNFSF13B,TNF,TNFRSF4,TNFRSF18,IL2RB
KLRC3,CD8A,B2M,CIITA,HLA-A,HLA-C,HLA-DQA2,HLA-G,HLA-F,KLRC1,KIR3DL1,KIR2DL4,CTSL1,TAP1,HLA-DPB1,KIR2DS4
KLRC3,IFNG,HLA-A,HLA-C,HLA-G,KLRC1,KIR3DL1,KIR2DL4,ITGB2,ZAP70,FCER1G,KIR2DS4,PTPN11,TNFSF10,FASLG,SH2D1A,NCR3,PRKCB,LCP2,PRF1,TNF,CD247
Let genes with copy number alteration or mutation be query genes. Let marker genes of specific identified subtypes be query genes. The Enrichment is calculated as:
-
Enrichment = log2 (# of query genes in the pathway/# No of query genes) - log2 (# of genes in the pathway/# of human genes)
The statistical signficance of the pathways that are enriched with genes with copy number alteration or mutation, and the pathways that are enriched with markers genes of specific identified subtypes is measured by P value.
-
P value = Fisher exact P value
The Q value is for adjusting P value for multiple testing. A public available R package is used to calculate the Q value.
This is an experimental feature. The full results of the analysis summarized in this report can be downloaded from the TCGA Data Coordination Center.